Thrivent Financial for Lutherans Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Thrivent Financial for Lutherans significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 492.0% in the fourth quarter, now owning 88,950 shares valued at $7.21 million. The article also details other institutional investor activity, LeMaitre Vascular's financial performance, recent insider selling, and current analyst ratings, with the stock holding a "Moderate Buy" consensus.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in two investor conferences in June 2026. Management will be engaging in a fireside chat at the Jefferies Global Healthcare Conference on June 3rd and presenting at the Goldman Sachs Annual Global Healthcare Conference on June 10th. LeMaitre is a provider of devices and services for peripheral vascular disease.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Management will engage in a fireside chat at the Jefferies conference and provide a presentation at the Goldman Sachs event. The company specializes in devices and services for peripheral vascular disease.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in June. Management will attend the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026. The company specializes in devices for peripheral vascular disease.
LeMaitre schedules June talks at Jefferies and Goldman healthcare events
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its management will participate in two investor conferences in June 2026. The company will attend the Jefferies Global Healthcare Conference in New York on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference in Miami Beach on June 10, 2026, delivering scheduled presentations at both events. LeMaitre, a provider of devices for peripheral vascular disease, aims to engage with investors and share company updates.
LeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in two investor conferences in June: the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026. Management will hold a fireside chat at the former and present at the latter. The company specializes in medical devices for peripheral vascular disease.
GSA Capital Partners LLP Has $1.72 Million Position in LeMaitre Vascular, Inc. $LMAT
GSA Capital Partners LLP significantly increased its stake in LeMaitre Vascular, Inc., now holding 21,234 shares valued at $1.72 million. This comes as other institutional investors have also adjusted their positions, and company insiders have recently sold shares. Analysts have a "Moderate Buy" consensus rating for LeMaitre Vascular, with a price target of $112.60.
Three Healthcare Stocks Facing Potential Headwinds in 2026
The article highlights three healthcare stocks - Envista Holdings, LeMaitre Vascular, and Brookdale Senior Living - that are expected to face challenges in 2026. The broader healthcare sector is experiencing uneven performance due to past COVID inventory offloading and increased competition from venture capital. These companies exhibit issues such as muted revenue growth, negative returns on capital, high forward P/E ratios, and flat or declining sales forecasts.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of "Moderate Buy" from Analysts
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $112.60. The company recently reported strong Q1 earnings, beating EPS expectations, and announced a quarterly dividend of $0.25 per share. Insider selling by directors Bridget A. Ross and David B. Roberts has also been noted.
Wakefield Asset Management LLLP Buys New Position in LeMaitre Vascular, Inc. $LMAT
Wakefield Asset Management LLLP has acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT), purchasing 13,933 shares valued at approximately $1.13 million. This comes as several hedge funds have adjusted their positions in the medical instruments supplier. Analysts currently rate LeMaitre Vascular as a "Moderate Buy" with an average price target of $112.60, following the company's Q1 earnings beat and 11.1% revenue growth year-over-year.
LeMaitre Vascular Senior Vice President of Operations Trent Kamke Sells 44% Of Holding
NULL
LeMaitre Vascular stock (US52567J1079): Q1 beat and raised 2026 guidance
LeMaitre Vascular reported strong Q1 2026 results with revenue up 11% to $66.55 million and net income of $15.68 million. The company raised its full-year 2026 sales guidance to $277-283 million and issued a quarterly dividend of $0.25 per share. Growth was driven by grafts, valvulotomes, and carotid shunts, with significant regional sales increases in EMEA and APAC.
[SCHEDULE 13G/A] LEMAITRE VASCULAR INC Amended Passive Investment Disclosure
George W. LeMaitre has filed an amended passive investment disclosure (Schedule 13G/A) for LeMaitre Vascular, Inc. (LMAT), reporting beneficial ownership of 1,465,235 shares of common stock, which represents 6.4% of the outstanding class as of March 31, 2026. This ownership includes 6,847 shares subject to options exercisable within 60 days. The filing indicates sole voting and dispositive power over these shares, documenting a meaningful individual stake without suggesting a change in control intentions.
Why LeMaitre Vascular (LMAT) Is Down 10.9% After Raising 2026 Guidance And Boosting Dividends
LeMaitre Vascular (LMAT) experienced a 10.9% stock decline despite reporting stronger Q1 sales and net income, raising its full-year 2026 guidance, and increasing its quarterly dividend. The company's updated outlook highlights management's confidence but also brings focus to risks around the sustainability of price increases and product concentration. Investors are encouraged to assess whether margin expansions, partly due to pricing, can be maintained in the long term.
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre Vascular (LMAT) has experienced a 17.2% decline in its stock price over the past four weeks but is now considered oversold based on its Relative Strength Index (RSI) of 28.47, suggesting a potential trend reversal. This technical indicator, combined with a 3.7% increase in consensus EPS estimates for the current year from Wall Street analysts and a Zacks Rank #2 (Buy), indicates that LMAT is ripe for a rebound. Investors may find an entry opportunity due to unwarranted selling pressure and the expectation of better future earnings.
LeMaitre Vascular (LMAT) director exercises options and sells 5,044 shares
LeMaitre Vascular director Bridget A. Ross executed an exercise-and-sale transaction, acquiring 5,044 shares through stock options and simultaneously selling the same number of shares on the open market. The transactions occurred on May 7, 2026, with option exercise prices of $47.19 and $48.60, and a weighted average sale price of $111.0956 per share. Following these transactions, Ross directly owns 3,942 Common Stock shares.
LeMaitre Vascular stock (US52567J1079): Insiders sell amid recent price drop
LeMaitre Vascular (NASDAQ:LMAT) shares dropped 5.8% to $101.64 on May 11, 2026, following significant insider sales by executives, including CEO George W. LeMaitre. This decline occurred despite the company reporting strong Q1 earnings with EPS beating estimates and revenue increasing by 11.1%. The company remains a key player in the peripheral vascular device market, focusing on niche products for vascular surgery, and maintains a "Moderate Buy" analyst consensus.
Vanguard Group Inc. Boosts Stake in LeMaitre Vascular, Inc. $LMAT
Vanguard Group Inc. increased its stake in LeMaitre Vascular, Inc. by 1.4% in the fourth quarter of 2025, bringing its total holdings to 1,622,033 shares valued at approximately $131.5 million. This makes Vanguard Group Inc. the owner of 7.15% of the company. LeMaitre Vascular recently reported strong quarterly results, exceeding EPS and revenue expectations, and also announced a quarterly dividend, despite notable insider stock sales.
LeMaitre Vascular CEO George LeMaitre sells $5.03m in stock
George W. LeMaitre, CEO of LeMaitre Vascular Inc. (NASDAQ:LMAT), recently sold company stock worth approximately $5.03 million. These sales occurred on May 7 and May 8, 2026, with shares trading at weighted average prices between $107.6351 and $108.6905. Following these transactions, Mr. LeMaitre directly holds over 1.4 million shares, with an additional 33,400 shares held indirectly through a trust.
Insider Sell: Trent Kamke Sells Shares of LeMaitre Vascular Inc (LMAT)
Trent Kamke, Senior Vice President of Operations at LeMaitre Vascular Inc (LMAT), sold 2,928 shares of the company on May 8, 2026. This transaction continues a trend over the past year where Kamke has sold a total of 6,597 shares with no purchases. The stock was trading at $107 per share, and with a price-to-GF-Value ratio of 1.12, GuruFocus indicates LeMaitre Vascular Inc is fairly valued.
Bridget Ross Sells 5,044 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock
LeMaitre Vascular director Bridget Ross recently sold 5,044 shares of LMAT stock for over $560,000, reducing her stake by more than 56%. This insider selling occurred despite the company topping quarterly EPS estimates, growing revenue by 11.1%, and declaring a $0.25 quarterly dividend. The stock traded down 5.8% following the news, reaching $101.64.
LeMaitre Vascular (NASDAQ:LMAT) Insider Trent Kamke Sells 2,928 Shares
LeMaitre Vascular insider Trent Kamke sold 2,928 shares of the company's stock for over $313,000, reducing his ownership by nearly 44%. The company recently reported better-than-expected quarterly earnings and revenue, and declared a quarterly dividend of $0.25 per share. Analysts currently rate the stock as a "Moderate Buy" with a consensus target price of $112.60.
LeMaitre Vascular (LMAT) CEO sells 46,481 shares, retains over 1.4M
LeMaitre Vascular (LMAT) Chairman and CEO George W. LeMaitre sold a total of 46,481 common shares in open-market transactions on May 7 and May 8, 2026. The sales were executed at weighted average prices of $107.6351 and $108.6905 per share, respectively. Despite these sales, LeMaitre retains a significant direct holding of 1,430,019 shares and an additional 33,400 shares indirectly through an irrevocable trust for his children.
LeMaitre Vascular CEO George LeMaitre sells $5.03m in stock
George W. LeMaitre, CEO of LeMaitre Vascular Inc., sold company stock worth approximately $5.03 million on May 7 and May 8, 2026. These sales occurred at weighted average prices between $107.6351 and $108.6905, with the stock declining nearly 9% since the transactions. Despite the stock sale, LeMaitre Vascular recently reported strong Q1 2026 earnings, surpassing analyst expectations, and received a raised price target from Citizens.
LeMaitre (LMAT) senior VP sells 2,928 shares in open-market trade
LeMaitre Vascular's Senior Vice President of Operations, Trent G. Kamke, sold 2,928 shares of common stock on May 8, 2026, in an open-market transaction. The shares were sold at a weighted average price of $106.9969, totaling approximately $313,287. Following this sale, Kamke directly holds 3,749 shares of LMAT.
Lemaitre Vascular senior V.P. Kamke sells $313k in stock
Trent G. Kamke, Senior V.P. of Operations at Lemaitre Vascular Inc. (NASDAQ:LMAT), sold 2,928 shares of company stock on May 8, 2026, for a total of approximately $313,286. Following the transaction, Kamke directly holds 3,749 shares. Despite the sell-off and an InvestingPro analysis suggesting LMAT is overvalued, the company recently surpassed Q1 2026 earnings and revenue forecasts, leading Citizens to raise its price target.
LeMaitre to Present at the Bank of America Healthcare Conference
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT. The company is a global provider of medical devices, implants, and services for treating peripheral vascular disease, focusing on vascular surgeons.
LeMaitre to Present at the Bank of America Healthcare Conference
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced it will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT. The company specializes in providing devices, implants, and services for the treatment of peripheral vascular disease. More information about LeMaitre, a provider of disposable and implantable vascular devices, can be found on their website.
Number of shareholders of LeMaitre Vascular, Inc. – NASDAQ:LMAT
This article provides details on how to find the number of shareholders for LeMaitre Vascular, Inc. (NASDAQ: LMAT) via TradingView. It indicates that shareholder information, including period, value, and change, can be accessed through their platform.
LeMaitre Vascular Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo has reiterated its "Equal-Weight" rating on LeMaitre Vascular (NASDAQ: LMAT). Further details of the report, including any price target, were not immediately available.
LeMaitre management takes Bank of America conference stage May 13
LeMaitre Vascular (Nasdaq: LMAT) announced that its management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT. The company, which specializes in devices for peripheral vascular disease, recently reported strong Q1 2026 financials, including $66.6 million in net sales and a 72.7% gross margin. Investors are encouraged to monitor future earnings and conference appearances for continued growth and profitability trends.
[144] LEMAITRE VASCULAR INC SEC Filing
This article reports on a Form 144 SEC filing by LEMAITRE VASCULAR INC (LMAT) on May 7, 2026. The filing indicates a proposed sale of 5044 shares of common stock with an aggregate market value of $560,366.40, acquired through a stock option exercise on the same day. The transaction involves Morgan Stanley Smith Barney LLC as the broker for the sale on NASDAQ.
LeMaitre to Present at the Bank of America Healthcare Conference
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT. The company specializes in providing devices, implants, and services for the treatment of peripheral vascular disease. More information about LeMaitre Vascular can be found on their website.
LeMaitre to Present at the Bank of America Healthcare Conference
LeMaitre Vascular, Inc. announced that its management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT. The company specializes in providing medical devices, implants, and services for treating peripheral vascular disease. More information about LeMaitre, including its products and market, is available on its website.
Barrington Research Raises LeMaitre Vascular (NASDAQ:LMAT) Price Target to $120.00
Barrington Research has raised its price target for LeMaitre Vascular (NASDAQ:LMAT) to $120.00 from $105.00, maintaining an "outperform" rating. This follows LeMaitre Vascular beating Q1 earnings estimates with $0.68 EPS and an 11.1% increase in revenue year-over-year, leading management to raise future guidance. Despite recent insider selling, institutional ownership remains high at 84.64%, and other analysts have also increased their price targets for the company.
LeMaitre Vascular (LMAT) Margin Improvement Reinforces Bullish Earnings Narratives
LeMaitre Vascular (LMAT) started 2026 with strong Q1 earnings, reporting US$66.6 million in revenue and US$0.69 basic EPS, contributing to a 31.1% earnings growth over the past year and a net margin of 23.1%. While analysts see robust growth drivers, valuation concerns arise as the company's P/E ratio is high compared to the US Medical Equipment industry average, and its shares trade significantly above the discounted cash flow fair value. Investors are left to weigh the positive margin and earnings growth against a potentially stretched valuation.
How LeMaitre Vascular’s Latest Earnings Test Will Impact LeMaitre Vascular (LMAT) Investors
LeMaitre Vascular (LMAT) recently reported its latest quarterly results, which are being closely watched by investors after the company previously exceeded revenue and EPS expectations. The earnings report will test whether their recent operational momentum and guidance strength can be sustained. Investors are focused on how closely these results align with the February 2026 guidance for Q1 and full year 2026, as questions remain regarding the durability of recent price-driven margin gains.
LeMaitre Vascular (LMAT) posts higher Q1 2026 sales, margins and cash flow
LeMaitre Vascular (LMAT) reported strong first-quarter 2026 results with an 11% increase in net sales to $66.6 million and a 42.4% rise in net income to $15.7 million compared to Q1 2025. This growth was driven by higher sales of grafts, valvulotomes, and shunts across all regions, improved gross margin of 72.7% due to pricing and manufacturing efficiencies, and robust operating cash flow. The company also increased its quarterly dividend to $0.25 per share and authorized a $100 million share repurchase program, while continuing to invest in global expansion and operational improvements.
LeMaitre Q1 2026 Financial Results
LeMaitre Vascular, Inc. (Nasdaq: LMAT) reported strong Q1 2026 results, with sales up 11% to $66.6 million and EPS increasing 42% to $0.68. The company announced a quarterly dividend of $0.25 per share and provided optimistic guidance for Q2 and the full year 2026, projecting continued sales and EPS growth driven by geographic expansion, higher pricing, and disciplined spending.
LeMaitre Vascular Sees 2026 Sales $277M-$283M >LMAT
LeMaitre Vascular (LMAT) projects its 2026 sales to be in the range of $277 million to $283 million. The article also briefly mentions Unity Software's Q4 financial results, reporting revenue of $609 million and a loss of 66 cents per share. The primary focus is on LeMaitre Vascular's sales forecast.
BRIEF-LeMaitre Vascular Q1 Sales USD 66.551 Million Vs. IBES Estimate USD 66.5 Million
LeMaitre Vascular reported Q1 sales of USD 66.551 million, narrowly exceeding the IBES estimate of USD 66.5 million. This brief update highlights the company's financial performance for the first quarter.
LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript
LeMaitre Vascular (NASDAQ: LMAT) announced strong Q1 2026 results, with sales up 11% and EPS up 42%. The company highlighted the success of its Autograph product line, particularly international growth, and plans to expand its sales force and develop new product lengths. Management also discussed M&A strategies focusing on niche markets in open vascular and cardiac surgery, while projecting continued strong financial performance with increased guidance for the full year 2026.
LeMaitre: Q1 Earnings Snapshot
LeMaitre Vascular Inc. reported first-quarter earnings of $15.7 million, or 68 cents per share, surpassing Wall Street expectations of 66 cents per share. However, the medical device maker's revenue of $66.6 million fell slightly short of analysts' forecasts. The company provided guidance for the current quarter, expecting revenue between $70.5 million and $72.5 million, and also issued full-year earnings and revenue forecasts.
LeMaitre Vascular (NASDAQ: LMAT) posts strong Q1 2026 results and raises 2026 growth outlook
LeMaitre Vascular (NASDAQ: LMAT) reported strong preliminary Q1 2026 results, with net sales of $66.6 million and diluted EPS growth of 42%. The company raised its full-year 2026 guidance, now projecting 12% sales growth and 26% adjusted EPS growth, driven by broad product and regional strength, as well as improved margins. Additionally, LeMaitre Vascular approved a quarterly dividend of $0.25 per share and authorized a $100 million share repurchase program.
LeMaitre: Q1 Earnings Snapshot
LeMaitre Vascular Inc. (LMAT) reported first-quarter earnings of $15.7 million, or 68 cents per share, surpassing Wall Street expectations of 66 cents per share. The medical device maker's revenue of $66.6 million for the period fell short of forecasts. LeMaitre provided revenue guidance for the current quarter ranging from $70.5 million to $72.5 million and full-year earnings expectations of $2.93 to $3.08 per share on revenue between $277 million and $283 million.
LeMaitre Q1 2026 Financial Results
LeMaitre Vascular, Inc. reported strong Q1 2026 results with sales up 11% to $66.6 million and EPS increasing by 42% to $0.68. The company attributes this growth to higher average selling prices, geographic expansion, and disciplined spending, leading to increased guidance for the full year 2026. LeMaitre also announced a quarterly dividend of $0.25 per share and initiated a share repurchase program of up to $100 million.
LeMaitre Q1 2026 Financial Results
LeMaitre Vascular, Inc. (Nasdaq: LMAT) reported strong Q1 2026 results, with sales up 11% to $66.6 million and EPS increasing by 42% to $0.68. The company announced a quarterly dividend of $0.25/share and provided increased guidance for Q2 and the full year 2026, projecting continued sales growth and adjusted EPS growth. Key performance drivers included robust growth in Artegraft, grafts, valvulotomes, and carotid shunts, alongside expanded gross margins and moderate operating expense growth.
LeMaitre (LMAT) Q1 Earnings Report Preview: What To Look For
LeMaitre Vascular (LMAT) is set to report its Q1 earnings, with market expectations for revenue growth of 11.4% year-on-year. The company had a strong previous quarter, exceeding both revenue and EPS estimates. Investors will be watching how LeMaitre's performance compares to peers like Intuitive Surgical and Baxter, who recently reported strong Q1 results.
(LMAT) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis for Lemaitre Vascular Inc. (NASDAQ: LMAT), highlighting weak near-term sentiment despite long-term strength. It outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, alongside multi-timeframe signal analysis for support and resistance levels. The analysis emphasizes an exceptional 35.6:1 risk-reward short setup.
Conestoga Capital Advisors LLC Trims Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Conestoga Capital Advisors LLC reduced its stake in LeMaitre Vascular, Inc. by 9.5% in the fourth quarter, selling 149,700 shares, though the stock remains its 23rd largest holding. The article highlights significant insider selling, including CEO George W. LeMaitre, alongside positive operational news such as beating EPS estimates, strong revenue growth, raised dividend, and favorable FY2026 EPS guidance. Several other institutional investors also adjusted their holdings in the medical instruments supplier.
